Biotech Values

[WorstLuck]

[ONCS]

"With the number of melanoma patients now being treated with either pembrolizumab or nivolumab in either the first- or second-line settings, there will be an increasing number of patients who will not respond to therapy. Thus, there is a clear need for treatments that can rescue these patients and help them benefit from these immunotherapies

Having apparently given up on first line intra-tumoral treatment they now hope to salvage the pipeline as a combination therapy.

This company had in the past been relying on their electroporation delivery as the primary investment thesis. There been little interest in intratumoral treatment irrespective of the delivery method.

Used to see this company as quasi-legitimate about five years ago.